美国心脏捐献循环死亡后再次移植早期经验
基于UNOS STAR数据(2019年1月1日至2025年10月1日)分析成人心脏再次移植受者,比较循环死亡后捐献(DCD)与脑死亡后捐献(DBD)的结局。474例再次移植中53例(11.2%)接受DCD心脏,DCD使用率在2025年升至32%。调整混杂后DCD与365天死亡率相关(HR 2.27,95%CI 1.02-5.02;p=0.044),倾向评分匹配队列中90天和365天生存率差异显著。
要点
- DCD心脏再次移植占比逐年上升,2025年达32%。
- DCD受者移植时病情较轻,ECMO和机械通气使用率更低。
- 调整分析显示DCD与365天死亡率升高相关,需谨慎选择受者。
核心结论
- DCD再次移植使用增加且集中于低危受者,风险调整和匹配分析显示供体类型与1年生存差异相关,支持谨慎且选择敏感的实施和持续评估。
研究设计与样本
- 基于UNOS STAR数据库(2019年1月1日至2025年10月1日)的回顾性队列研究,纳入474例成人心脏再次移植受者,比较DCD与DBD供体,并采用2:1倾向评分匹配(DCD n=51;DBD n=96)。
主要发现
- 474例再次移植中53例(11.2%)接受DCD心脏,DCD使用率在2025年升至32%(部分年份)。
- DCD受者移植时ECMO使用率1.9% vs 18.3%,机械通气0.0% vs 10.0%,分配状态差异显著(p<0.001),成人Status 4 listing更多(56.6% vs 26.6%)。
- 围术期并发症和早期死亡率供体类型间相似,未调整90天(log-rank p=0.51)和365天(p=0.42)生存无差异。
- 调整Cox回归中DCD vs DBD的365天死亡率HR 2.27(95%CI 1.02-5.02;p=0.044)。
- 匹配队列中供体类型在90天(p=0.03)和365天(p=0.009)生存差异显著。
临床怎么用
- DCD再次移植应优先选择病情较轻、未使用ECMO或机械通气的受者,并加强术后随访评估。
局限性
- 原文未明确报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Donation after circulatory death (DCD) expands the heart donor pool, but outcomes after adult heart retransplantation (re-TX) are not well defined. METHODS: Using UNOS STAR data (January 1, 2019 to October 1, 2025), we studied adults undergoing orthotopic re-TX. Exposure was donor mechanism (DCD vs donation after brain death [DBD]). The primary outcome was 365-day mortality assessed with Kaplan-Meier methods and multivariable Cox regression. We also performed 2:1 propensity-score matching (PSM) using prespecified covariates. RESULTS: Among 474 re-TX recipients, 53 (11.2%) received DCD hearts; DCD use rose to 32% of re-TX in 2025 (partial year). Compared with DBD, DCD recipients had lower transplant acuity (ECMO 1.9% vs 18.3%; mechanical ventilation 0.0% vs 10.0%) and differed in allocation status (p<0.001), with more Adult Status 4 listings (56.6% vs 26.6%). Perioperative complications and early mortality were similar by donor type. Unadjusted survival did not differ at 90 days (log-rank p=0.51) or 365 days (p=0.42). In adjusted Cox regression, donor mechanism was associated with 365-day mortality (DCD vs DBD hazard ratio 2.27, 95% CI 1.02-5.02; p=0.044). In the matched cohort (DCD n=51; DBD n=96), survival differed by donor mechanism at 90 days (p=0.03) and 365 days (p=0.009). CONCLUSIONS: DCD re-TX use is increasing and is concentrated in lower-acuity recipients. While perioperative outcomes were similar, risk-adjusted and matched analyses identified differences in 1-year survival by donor mechanism, supporting cautious, selection-sensitive implementation and continued evaluation as experience and follow-up accrue.
引用
- Berg AR, Krishnan A, Heng EE, et al. Early United States experience with donation after circulatory death for heart retransplantation. J Heart Lung Transplant. 2026. PMID: 42017890. doi:10.1016/j.healun.2026.02.1673
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。